靶向中轴型与外周型银屑病关节炎:乌帕替尼临床相关性的回顾性观察研究
该回顾性研究纳入意大利27家风湿病中心的425例银屑病关节炎患者,评估乌帕替尼对中轴和外周表现的有效性。12个月时乌帕替尼生存率为75.1%,外周型高于混合型(P=0.039);38.2%达到ASDAS-LDA,20.6%达到ASDAS-ID,MDA粗率为59.9%。
要点
- 12个月乌帕替尼生存率75.1%,外周型高于混合型(P=0.039)。
- 纤维肌痛是停药最强预测因素(aHR 1.72;95%CI 1.08-2.75;P=0.022)。
- 12个月ASDAS-LDA 38.2%、ASDAS-ID 20.6%,MDA粗率59.9%。
核心结论
- 研究证实乌帕替尼对银屑病关节炎各领域有效,中轴受累和疼痛有临床意义的改善。
研究设计与样本
- 回顾性研究,纳入意大利27家风湿病中心的425例银屑病关节炎患者,收集基线、6个月和12个月数据。
- 采用Kaplan-Meier曲线评估治疗持续性,多变量模型识别停药和结局的预测因素。
主要发现
- 425例患者中282例(66.4%)为外周型银屑病关节炎,143例(33.6%)为混合型(外周和中轴)银屑病关节炎。
- 12个月乌帕替尼生存率为75.1%,外周型高于混合型(P=0.039)。
- 纤维肌痛是停药最强预测因素(aHR 1.72;95%CI 1.08-2.75;P=0.022)。
- 12个月时38.2%的患者达到ASDAS-LDA,20.6%达到ASDAS-ID(LUNDEX校正率分别为29.4%和15.8%)。
- 12个月MDA粗率为59.9%(LUNDEX校正后为47.4%),附着点炎缓解率80.2%(P<0.001),NSAIDs使用降至32.9%(P<0.001)。
关键数值与推荐
- 总体VAS疼痛从71.4显著降至40(平均变化-31.4;95%CI:-42.5至-33.6;P<0.0001),降低44%,远高于最小临床重要改善。
- 未报告主要心血管事件;大多数不良事件为轻度,包括胃肠道不耐受(19%)、感染(9.5%)和肝酶升高(14.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate upadacitinib (UPA) effectiveness on axial and peripheral manifestations of PsA by assessing the proportion of patients achieving low disease activity (LDA) and inactive disease (ID) status for axial involvement, and MDA and DAPSA-defined remission/LDA for peripheral domain. METHODS: This retrospective study included PsA patients from 27 Italian rheumatology centres. Demographic, clinical and outcome data were collected at baseline, 6 and 12 months. Kaplan-Meier curves assessed treatment persistence. Multivariate models identified predictors of discontinuation and outcomes. RESULTS: Among the 425 patients, 282 (66.4%) had peripheral PsA and 143 (33.6%) mixed (peripheral and axial) PsA. The 12-month UPA survival rate was 75.1%, higher in peripheral than mixed PsA (P = 0.039). Fibromyalgia was the strongest predictor of discontinuation (aHR 1.72; 95% CI: 1.08-2.75; P = 0.022). At 12 months, 38.2% of patients achieved ASDAS-LDA and 20.6% reached ASDAS-ID (LUNDEX-adjusted rates were 29.4% and 15.8%, respectively). The crude 12-month MDA rate was 59.9% (47.4% after LUNDEX adjustment). Enthesitis resolved in 80.2% of patients (P < 0.001), and NSAIDs use decreased to 32.9% (P < 0.001). Overall, VAS pain decreased significantly from 71.4 to 40 (mean change -31.4; 95% CI: -42.5 to -33.6; P < 0.0001), with a 44% reduction, well above the minimal clinically important improvement. No major cardiovascular events were reported; most adverse events were mild, including gastrointestinal intolerance (19%), infections (9.5%) and elevated liver enzymes (14.2%). CONCLUSION: Our study confirms UPA effectiveness across PsA domains, with clinically meaningful improvements in axial involvement and pain.
引用
- Lopalco G, Celletti E, Morrone M, et al. Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib. Rheumatology (Oxford). 2025. PMID: 40758456. doi:10.1093/rheumatology/keaf411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。